Aligos Therapeutics, Inc. - Common stock (NQ:ALGS)
Price and Volume
Detailed Quote| Volume | 0 |
| Open | 7.300 |
| Bid (Size) | 7.310 (100) |
| Ask (Size) | 7.850 (300) |
| Prev. Close | 7.300 |
| Today's Range | 7.300 - 7.300 |
| 52wk Range | 3.760 - 13.69 |
| Shares Outstanding | 42,940,089 |
| Dividend Yield | N/A |
Top News
More News
Performance
More News
Read More
Earnings Scheduled For November 6, 2025 ↗
November 06, 2025
Aligos Therapeutics Presents Positive Data at HEP-DART 2025
December 11, 2025
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025
November 10, 2025
Aligos Therapeutics to Present at Upcoming Investor Conferences
November 04, 2025
Frequently Asked Questions
Is Aligos Therapeutics, Inc. - Common stock publicly traded?
Yes, Aligos Therapeutics, Inc. - Common stock is publicly traded.
What exchange does Aligos Therapeutics, Inc. - Common stock trade on?
Aligos Therapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aligos Therapeutics, Inc. - Common stock?
The ticker symbol for Aligos Therapeutics, Inc. - Common stock is ALGS on the Nasdaq Stock Market
What is the current price of Aligos Therapeutics, Inc. - Common stock?
The current price of Aligos Therapeutics, Inc. - Common stock is 7.300
When was Aligos Therapeutics, Inc. - Common stock last traded?
The last trade of Aligos Therapeutics, Inc. - Common stock was at 03/17/26 04:00 PM ET
What is the market capitalization of Aligos Therapeutics, Inc. - Common stock?
The market capitalization of Aligos Therapeutics, Inc. - Common stock is 313.46M
How many shares of Aligos Therapeutics, Inc. - Common stock are outstanding?
Aligos Therapeutics, Inc. - Common stock has 313M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
Facebook
Twitter
YouTube